These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 10609850)

  • 21. Is losartan superior to captopril in reducing all-cause mortality in elderly patients with symptomatic heart failure?
    Trojian TH; Jackson EA
    J Fam Pract; 2000 Aug; 49(8):759-60. PubMed ID: 10947144
    [No Abstract]   [Full Text] [Related]  

  • 22. The effects of angiotensin receptor antagonists on mortality and morbidity in heart failure--and an interaction with beta blockade.
    Coats AJ
    Int J Cardiol; 2001 Jan; 77(1):1-4. PubMed ID: 11150619
    [No Abstract]   [Full Text] [Related]  

  • 23. Angiotensin-converting enzyme inhibitors and survival in women and men with heart failure.
    Keyhan G; Chen SF; Pilote L
    Eur J Heart Fail; 2007; 9(6-7):594-601. PubMed ID: 17462947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cardiac insufficiency: what treatment? what dose? For which patients? Converting enzyme inhibitors and diuretics].
    Komajda M
    Arch Mal Coeur Vaiss; 2000 Feb; 93 Spec No 2():13-6. PubMed ID: 10830083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of converting enzyme inhibitors in cardiac insufficiency mortality in the elderly].
    Kirancumar ; dos Reis RP; Correia JF
    Rev Port Cardiol; 1992 Jun; 11(6):553-8. PubMed ID: 1503788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A three year clinical review of the impact of angiotensin converting enzyme inhibitors on the intra hospital mortality of congestive heart failure in Nigerians.
    Adewole AD; Ikem RT; Adigun AQ; Akintomide AO; Balogun MO; Ajayi AA
    Cent Afr J Med; 1996 Aug; 42(8):253-5. PubMed ID: 8990572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does losartan decrease all-cause mortality more than placebo or first-generation ACE inhibitors for patients with moderate to severe heart failure?
    LeClair BM
    J Fam Pract; 2000 May; 49(5):397. PubMed ID: 10836767
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of ACE inhibitors.
    Widimský J
    Cor Vasa; 1992; 34(1):1-3. PubMed ID: 1288940
    [No Abstract]   [Full Text] [Related]  

  • 29. Impact of advances in therapy for heart failure on secular trends in mortality.
    Rector TS
    J Card Fail; 1996 Mar; 2(1):31-2. PubMed ID: 8798102
    [No Abstract]   [Full Text] [Related]  

  • 30. Pleiotropic effects of angiotensin-converting enzyme inhibitors and the future of cachexia therapy.
    von Haehling S; Sandek A; Anker SD
    J Am Geriatr Soc; 2005 Nov; 53(11):2030-1. PubMed ID: 16274392
    [No Abstract]   [Full Text] [Related]  

  • 31. [Current role of angiotensin II antagonists in the treatment of heart failure].
    Porcu M; Orrù P
    Ital Heart J Suppl; 2000 Sep; 1(9):1213-4. PubMed ID: 11140296
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of combination angiotensin-converting enzyme and angiotensin receptor blocker therapy on heart failure mortality and morbidity.
    Kapoor JR
    Am J Cardiol; 2008 Mar; 101(5):744-5. PubMed ID: 18308033
    [No Abstract]   [Full Text] [Related]  

  • 33. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA; Movahed A
    Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin-converting enzyme inhibitors (ACE) in congestive heart failure.
    Fukuyama O
    Arch Intern Med; 1991 Aug; 151(8):1669-70. PubMed ID: 1872676
    [No Abstract]   [Full Text] [Related]  

  • 35. [Angiotensin converting enzyme inhibitors in the treatment of heart failure].
    Bettencourt P; Ferreira A
    Rev Port Cardiol; 2000 Dec; 19 Suppl 2():II51-6. PubMed ID: 11301911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ACE inhibitors still the drug of choice for heart failure--and more.
    Topol E
    Lancet; 1999 Nov; 354(9192):1797. PubMed ID: 10577651
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacotherapy of systolic heart failure: emphasis on mortality outcomes.
    Barbour MM; Zuwallack A
    Med Health R I; 2001 Feb; 84(2):55-8. PubMed ID: 11272661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug therapy for chronic heart failure due to left ventricular systolic dysfunction: a review. III. Angiotensin-converting enzyme inhibitors.
    Ascenção R; Fortuna P; Reis I; Carneiro AV
    Rev Port Cardiol; 2008 Sep; 27(9):1169-87. PubMed ID: 19044179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amlodipine in chronic heart failure.
    Allan JJ
    N Engl J Med; 1997 Apr; 336(14):1023-4; author reply 1024. PubMed ID: 9091790
    [No Abstract]   [Full Text] [Related]  

  • 40. Are angiotensin-receptor blockers (ARBs) equivalent to or better than angiotensin-converting enzyme (ACE) inhibitors in the treatment of heart failure?
    Reigle J
    Crit Care Nurse; 2004 Dec; 24(6):67-9. PubMed ID: 15646090
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.